Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621673 · ClinicalTrials.gov registry record · Phase 4
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00621673 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 1 participants.
The verdict
NCT00621673, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when switched from their current recombinant therapy produced from Chinese Hamster Ovary (CHO) cell line to Kogenate-FS raised in a Baby Hamster Kidney cell line.
Interventions
- DRUG Kogenate (BAY 14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621673
The ClinicalTrials.gov registry entry for NCT00621673 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kogenate (BAY 14-2222) is the first listed.
NCT00621673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621673 about?
NCT00621673 is a clinical study titled "Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A". Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when switched from their current recombinant therapy produced from Chinese Hamster...
What is the current status of trial NCT00621673?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00621673?
The interventions under investigation include: Kogenate (BAY 14-2222) (DRUG).
Who is sponsoring clinical trial NCT00621673?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.